Loading…
Hypertrophied hearts: what of sevoflurane cardioprotection?
Background: Recent studies have demonstrated that inhalation anaesthetics, like sevoflurane, confer cardioprotection both experimentally and clinically. However, coexisting cardiac disease might diminish anaesthetic cardioprotection and could partly explain why the clinical results of cardioprotecti...
Saved in:
| Published in: | Acta anaesthesiologica Scandinavica 2009-04, Vol.53 (4), p.496-504 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c4359-7b324e11b5e87aa0375c5e2afbaff1476fc2dab5ddcc74bb66e31e93ff5a1aaa3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c4359-7b324e11b5e87aa0375c5e2afbaff1476fc2dab5ddcc74bb66e31e93ff5a1aaa3 |
| container_end_page | 504 |
| container_issue | 4 |
| container_start_page | 496 |
| container_title | Acta anaesthesiologica Scandinavica |
| container_volume | 53 |
| creator | LARSEN, J. R. SMERUP, M. HASENKAM, J. M. CHRISTENSEN, S. D. SIVESGAARD, K. TORP, P. SLOTH, E. |
| description | Background: Recent studies have demonstrated that inhalation anaesthetics, like sevoflurane, confer cardioprotection both experimentally and clinically. However, coexisting cardiac disease might diminish anaesthetic cardioprotection and could partly explain why the clinical results of cardioprotection with anaesthetics remain controversial – in contrast to solid experimental evidence. Concomitant left ventricular hypertrophy is found in some cardiac surgery patients and could change cardioprotection efficacy. Hypertrophy could potentially render the heart less susceptible to sevoflurane cardioprotection and more susceptible to ischaemic injury. We investigated whether hypertrophy blocks sevoflurane cardioprotection, and whether tolerance to ischaemia is altered by left ventricular hypertrophy, in an established experimental animal model of ischaemia–reperfusion.
Methods: Anaesthetized juvenile pigs (n=7–12/group) were subjected to 45 min distal coronary artery balloon occlusion, followed by 120 min of reperfusion. Controls were given pentobarbital, while sevoflurane cardioprotection was achieved by 3.2% inhalation throughout the experiment. Chronic banding of the ascending aorta resulted in left ventricular hypertrophy development in two further groups and these animals underwent identical ischaemia–reperfusion protocols, with or without sevoflurane cardioprotection. Myocardial infarct sizes were compared post‐mortem.
Results: The mean myocardial infarct size (% of area‐at‐risk) was reduced from mean 55.0 (13.6%) (±SD) in controls to 17.5 (13.2%) by sevoflurane (P=0.001). Sevoflurane reduced the infarct size in hypertrophied hearts to 14.6 (10.4%) (P=0.001); however, in hypertrophic controls, infarcts were reduced to 34.2 (10.2%) (P=0.001).
Conclusion: Sevoflurane abrogated ischaemic injury to similar levels in both normal and left ventricular hypertrophied hearts. |
| doi_str_mv | 10.1111/j.1399-6576.2008.01889.x |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67068060</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67068060</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4359-7b324e11b5e87aa0375c5e2afbaff1476fc2dab5ddcc74bb66e31e93ff5a1aaa3</originalsourceid><addsrcrecordid>eNqNkFFv0zAQxy0EYt3gK6C8wFuCL47tGIRQtcGGNA0hQEy8WBfnrKakS7FT1n57HFp1r_jFtvz7351_jGXAC0jr9bIAYUyupFZFyXldcKhrU2wfsdnx4TGbcc4hl6DLE3Ya4zJdRWXMU3YCRoCulZyxt1e7NYUxDOtFR222IAxjfJPdL3DMBp9F-jP4fhPwjjKHoe2GdRhGcmM33L1_xp547CM9P-xn7PvHD9_Or_Lrz5efzufXuauENLluRFkRQCOp1ohcaOkklegb9B4qrbwrW2xk2zqnq6ZRigSQEd5LBEQUZ-zVvm7q_XtDcbSrLjrq-zTVsIlWaa5qrngC6z3owhBjIG_XoVth2FngdhJnl3byYyc_dhJn_4mz2xR9ceixaVbUPgQPphLw8gBgdNj7pMR18ciVUFbK1CZx7_bcfdfT7r8HsPP51-mU8vk-38WRtsc8hl_pn0md_XFzaeH2C1z8VLfWiL_kqJnk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67068060</pqid></control><display><type>article</type><title>Hypertrophied hearts: what of sevoflurane cardioprotection?</title><source>Wiley</source><creator>LARSEN, J. R. ; SMERUP, M. ; HASENKAM, J. M. ; CHRISTENSEN, S. D. ; SIVESGAARD, K. ; TORP, P. ; SLOTH, E.</creator><creatorcontrib>LARSEN, J. R. ; SMERUP, M. ; HASENKAM, J. M. ; CHRISTENSEN, S. D. ; SIVESGAARD, K. ; TORP, P. ; SLOTH, E.</creatorcontrib><description>Background: Recent studies have demonstrated that inhalation anaesthetics, like sevoflurane, confer cardioprotection both experimentally and clinically. However, coexisting cardiac disease might diminish anaesthetic cardioprotection and could partly explain why the clinical results of cardioprotection with anaesthetics remain controversial – in contrast to solid experimental evidence. Concomitant left ventricular hypertrophy is found in some cardiac surgery patients and could change cardioprotection efficacy. Hypertrophy could potentially render the heart less susceptible to sevoflurane cardioprotection and more susceptible to ischaemic injury. We investigated whether hypertrophy blocks sevoflurane cardioprotection, and whether tolerance to ischaemia is altered by left ventricular hypertrophy, in an established experimental animal model of ischaemia–reperfusion.
Methods: Anaesthetized juvenile pigs (n=7–12/group) were subjected to 45 min distal coronary artery balloon occlusion, followed by 120 min of reperfusion. Controls were given pentobarbital, while sevoflurane cardioprotection was achieved by 3.2% inhalation throughout the experiment. Chronic banding of the ascending aorta resulted in left ventricular hypertrophy development in two further groups and these animals underwent identical ischaemia–reperfusion protocols, with or without sevoflurane cardioprotection. Myocardial infarct sizes were compared post‐mortem.
Results: The mean myocardial infarct size (% of area‐at‐risk) was reduced from mean 55.0 (13.6%) (±SD) in controls to 17.5 (13.2%) by sevoflurane (P=0.001). Sevoflurane reduced the infarct size in hypertrophied hearts to 14.6 (10.4%) (P=0.001); however, in hypertrophic controls, infarcts were reduced to 34.2 (10.2%) (P=0.001).
Conclusion: Sevoflurane abrogated ischaemic injury to similar levels in both normal and left ventricular hypertrophied hearts.</description><identifier>ISSN: 0001-5172</identifier><identifier>EISSN: 1399-6576</identifier><identifier>DOI: 10.1111/j.1399-6576.2008.01889.x</identifier><identifier>PMID: 19317865</identifier><identifier>CODEN: AANEAB</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Anesthesia ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Anesthetics, Inhalation - pharmacology ; Animals ; Biological and medical sciences ; Disease Models, Animal ; Female ; Hypertrophy, Left Ventricular - complications ; Medical sciences ; Methyl Ethers - pharmacology ; Myocardial Infarction - drug therapy ; Swine</subject><ispartof>Acta anaesthesiologica Scandinavica, 2009-04, Vol.53 (4), p.496-504</ispartof><rights>2009 The Authors. Journal compilation © 2009 The Acta Anaesthesiologica Scandinavica Foundation</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4359-7b324e11b5e87aa0375c5e2afbaff1476fc2dab5ddcc74bb66e31e93ff5a1aaa3</citedby><cites>FETCH-LOGICAL-c4359-7b324e11b5e87aa0375c5e2afbaff1476fc2dab5ddcc74bb66e31e93ff5a1aaa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1399-6576.2008.01889.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1399-6576.2008.01889.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,786,790,27957,27958,50923,51032</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21246989$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19317865$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>LARSEN, J. R.</creatorcontrib><creatorcontrib>SMERUP, M.</creatorcontrib><creatorcontrib>HASENKAM, J. M.</creatorcontrib><creatorcontrib>CHRISTENSEN, S. D.</creatorcontrib><creatorcontrib>SIVESGAARD, K.</creatorcontrib><creatorcontrib>TORP, P.</creatorcontrib><creatorcontrib>SLOTH, E.</creatorcontrib><title>Hypertrophied hearts: what of sevoflurane cardioprotection?</title><title>Acta anaesthesiologica Scandinavica</title><addtitle>Acta Anaesthesiol Scand</addtitle><description>Background: Recent studies have demonstrated that inhalation anaesthetics, like sevoflurane, confer cardioprotection both experimentally and clinically. However, coexisting cardiac disease might diminish anaesthetic cardioprotection and could partly explain why the clinical results of cardioprotection with anaesthetics remain controversial – in contrast to solid experimental evidence. Concomitant left ventricular hypertrophy is found in some cardiac surgery patients and could change cardioprotection efficacy. Hypertrophy could potentially render the heart less susceptible to sevoflurane cardioprotection and more susceptible to ischaemic injury. We investigated whether hypertrophy blocks sevoflurane cardioprotection, and whether tolerance to ischaemia is altered by left ventricular hypertrophy, in an established experimental animal model of ischaemia–reperfusion.
Methods: Anaesthetized juvenile pigs (n=7–12/group) were subjected to 45 min distal coronary artery balloon occlusion, followed by 120 min of reperfusion. Controls were given pentobarbital, while sevoflurane cardioprotection was achieved by 3.2% inhalation throughout the experiment. Chronic banding of the ascending aorta resulted in left ventricular hypertrophy development in two further groups and these animals underwent identical ischaemia–reperfusion protocols, with or without sevoflurane cardioprotection. Myocardial infarct sizes were compared post‐mortem.
Results: The mean myocardial infarct size (% of area‐at‐risk) was reduced from mean 55.0 (13.6%) (±SD) in controls to 17.5 (13.2%) by sevoflurane (P=0.001). Sevoflurane reduced the infarct size in hypertrophied hearts to 14.6 (10.4%) (P=0.001); however, in hypertrophic controls, infarcts were reduced to 34.2 (10.2%) (P=0.001).
Conclusion: Sevoflurane abrogated ischaemic injury to similar levels in both normal and left ventricular hypertrophied hearts.</description><subject>Anesthesia</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Anesthetics, Inhalation - pharmacology</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Disease Models, Animal</subject><subject>Female</subject><subject>Hypertrophy, Left Ventricular - complications</subject><subject>Medical sciences</subject><subject>Methyl Ethers - pharmacology</subject><subject>Myocardial Infarction - drug therapy</subject><subject>Swine</subject><issn>0001-5172</issn><issn>1399-6576</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNqNkFFv0zAQxy0EYt3gK6C8wFuCL47tGIRQtcGGNA0hQEy8WBfnrKakS7FT1n57HFp1r_jFtvz7351_jGXAC0jr9bIAYUyupFZFyXldcKhrU2wfsdnx4TGbcc4hl6DLE3Ya4zJdRWXMU3YCRoCulZyxt1e7NYUxDOtFR222IAxjfJPdL3DMBp9F-jP4fhPwjjKHoe2GdRhGcmM33L1_xp547CM9P-xn7PvHD9_Or_Lrz5efzufXuauENLluRFkRQCOp1ohcaOkklegb9B4qrbwrW2xk2zqnq6ZRigSQEd5LBEQUZ-zVvm7q_XtDcbSrLjrq-zTVsIlWaa5qrngC6z3owhBjIG_XoVth2FngdhJnl3byYyc_dhJn_4mz2xR9ceixaVbUPgQPphLw8gBgdNj7pMR18ciVUFbK1CZx7_bcfdfT7r8HsPP51-mU8vk-38WRtsc8hl_pn0md_XFzaeH2C1z8VLfWiL_kqJnk</recordid><startdate>200904</startdate><enddate>200904</enddate><creator>LARSEN, J. R.</creator><creator>SMERUP, M.</creator><creator>HASENKAM, J. M.</creator><creator>CHRISTENSEN, S. D.</creator><creator>SIVESGAARD, K.</creator><creator>TORP, P.</creator><creator>SLOTH, E.</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200904</creationdate><title>Hypertrophied hearts: what of sevoflurane cardioprotection?</title><author>LARSEN, J. R. ; SMERUP, M. ; HASENKAM, J. M. ; CHRISTENSEN, S. D. ; SIVESGAARD, K. ; TORP, P. ; SLOTH, E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4359-7b324e11b5e87aa0375c5e2afbaff1476fc2dab5ddcc74bb66e31e93ff5a1aaa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Anesthesia</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Anesthetics, Inhalation - pharmacology</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Disease Models, Animal</topic><topic>Female</topic><topic>Hypertrophy, Left Ventricular - complications</topic><topic>Medical sciences</topic><topic>Methyl Ethers - pharmacology</topic><topic>Myocardial Infarction - drug therapy</topic><topic>Swine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>LARSEN, J. R.</creatorcontrib><creatorcontrib>SMERUP, M.</creatorcontrib><creatorcontrib>HASENKAM, J. M.</creatorcontrib><creatorcontrib>CHRISTENSEN, S. D.</creatorcontrib><creatorcontrib>SIVESGAARD, K.</creatorcontrib><creatorcontrib>TORP, P.</creatorcontrib><creatorcontrib>SLOTH, E.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Acta anaesthesiologica Scandinavica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>LARSEN, J. R.</au><au>SMERUP, M.</au><au>HASENKAM, J. M.</au><au>CHRISTENSEN, S. D.</au><au>SIVESGAARD, K.</au><au>TORP, P.</au><au>SLOTH, E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hypertrophied hearts: what of sevoflurane cardioprotection?</atitle><jtitle>Acta anaesthesiologica Scandinavica</jtitle><addtitle>Acta Anaesthesiol Scand</addtitle><date>2009-04</date><risdate>2009</risdate><volume>53</volume><issue>4</issue><spage>496</spage><epage>504</epage><pages>496-504</pages><issn>0001-5172</issn><eissn>1399-6576</eissn><coden>AANEAB</coden><notes>istex:79159B7839AEF47296608FA5A51E6937E062AB5B</notes><notes>ark:/67375/WNG-1XQ1DZ6X-9</notes><notes>ArticleID:AAS1889</notes><notes>Presented in part at the 57th Annual Meeting of the Scandinavian Association of Thoracic Surgery (SATS), Copenhagen, 21–23 August 2008.</notes><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><abstract>Background: Recent studies have demonstrated that inhalation anaesthetics, like sevoflurane, confer cardioprotection both experimentally and clinically. However, coexisting cardiac disease might diminish anaesthetic cardioprotection and could partly explain why the clinical results of cardioprotection with anaesthetics remain controversial – in contrast to solid experimental evidence. Concomitant left ventricular hypertrophy is found in some cardiac surgery patients and could change cardioprotection efficacy. Hypertrophy could potentially render the heart less susceptible to sevoflurane cardioprotection and more susceptible to ischaemic injury. We investigated whether hypertrophy blocks sevoflurane cardioprotection, and whether tolerance to ischaemia is altered by left ventricular hypertrophy, in an established experimental animal model of ischaemia–reperfusion.
Methods: Anaesthetized juvenile pigs (n=7–12/group) were subjected to 45 min distal coronary artery balloon occlusion, followed by 120 min of reperfusion. Controls were given pentobarbital, while sevoflurane cardioprotection was achieved by 3.2% inhalation throughout the experiment. Chronic banding of the ascending aorta resulted in left ventricular hypertrophy development in two further groups and these animals underwent identical ischaemia–reperfusion protocols, with or without sevoflurane cardioprotection. Myocardial infarct sizes were compared post‐mortem.
Results: The mean myocardial infarct size (% of area‐at‐risk) was reduced from mean 55.0 (13.6%) (±SD) in controls to 17.5 (13.2%) by sevoflurane (P=0.001). Sevoflurane reduced the infarct size in hypertrophied hearts to 14.6 (10.4%) (P=0.001); however, in hypertrophic controls, infarcts were reduced to 34.2 (10.2%) (P=0.001).
Conclusion: Sevoflurane abrogated ischaemic injury to similar levels in both normal and left ventricular hypertrophied hearts.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>19317865</pmid><doi>10.1111/j.1399-6576.2008.01889.x</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0001-5172 |
| ispartof | Acta anaesthesiologica Scandinavica, 2009-04, Vol.53 (4), p.496-504 |
| issn | 0001-5172 1399-6576 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67068060 |
| source | Wiley |
| subjects | Anesthesia Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Anesthetics, Inhalation - pharmacology Animals Biological and medical sciences Disease Models, Animal Female Hypertrophy, Left Ventricular - complications Medical sciences Methyl Ethers - pharmacology Myocardial Infarction - drug therapy Swine |
| title | Hypertrophied hearts: what of sevoflurane cardioprotection? |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T10%3A28%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hypertrophied%20hearts:%20what%20of%20sevoflurane%20cardioprotection?&rft.jtitle=Acta%20anaesthesiologica%20Scandinavica&rft.au=LARSEN,%20J.%20R.&rft.date=2009-04&rft.volume=53&rft.issue=4&rft.spage=496&rft.epage=504&rft.pages=496-504&rft.issn=0001-5172&rft.eissn=1399-6576&rft.coden=AANEAB&rft_id=info:doi/10.1111/j.1399-6576.2008.01889.x&rft_dat=%3Cproquest_cross%3E67068060%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4359-7b324e11b5e87aa0375c5e2afbaff1476fc2dab5ddcc74bb66e31e93ff5a1aaa3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=67068060&rft_id=info:pmid/19317865&rfr_iscdi=true |